A5079485962- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- DNA Repair Mechanisms
- Nuclear Structure and Function
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Prostate Cancer Treatment and Research
- Lipoproteins and Cardiovascular Health
- Renal cell carcinoma treatment
- Endometriosis Research and Treatment
- Estrogen and related hormone effects
- Cervical Cancer and HPV Research
- Intraperitoneal and Appendiceal Malignancies
- Advanced Breast Cancer Therapies
- RNA Research and Splicing
- Lung Cancer Treatments and Mutations
- CRISPR and Genetic Engineering
- Economic and Financial Impacts of Cancer
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Toxin Mechanisms and Immunotoxins
Rigshospitalet
2016-2025
Copenhagen University Hospital
2016-2025
Nordic Society of Gynecologic Oncology
2016-2025
Aurora West Allis Medical Center
2022-2023
University of Karachi
2023
International Center for Chemical and Biological Sciences
2023
Danish Cancer Society
2023
Aurora Health Care
2022
Aalborg University Hospital
2006-2022
Aarhus University Hospital
2006-2022
In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab active alone and in combination. AURELIA the first randomized phase III trial to our knowledge combining bevacizumab with OC.Eligible patients had measurable/assessable OC that progressed < 6 months after completing platinum-based therapy. Patients refractory disease, history of bowel obstruction, or > two prior anticancer regimens were ineligible. After investigators selected (pegylated liposomal...
A European consensus conference on endometrial carcinoma was held in 2014 to produce multi-disciplinary evidence-based guidelines selected questions. Given the large body of literature management published since 2014, Society Gynaecological Oncology (ESGO), SocieTy for Radiotherapy and (ESTRO), Pathology (ESP) jointly decided update these cover new topics order improve quality care women with across Europe worldwide.
The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer the addition of bevacizumab to standard chemotherapy, greatest effect patients at high risk disease progression. We report final overall results trial.ICON7 was an international, phase 3, open-label, randomised undertaken 263 centres 11 countries across Europe, Canada, Australia and New Zealand. Eligible adult newly diagnosed that either high-risk early-stage (International Federation...
<h3>Abstract</h3> The first joint European Society for Medical Oncology (ESMO), SocieTy Radiotherapy & (ESTRO) and of Gynaecological (ESGO) consensus conference on endometrial cancer was held 11–13 December 2014 in Milan, Italy, comprised a multidisciplinary panel 40 leading experts the management cancer. Before conference, expert prepared three clinically-relevant questions about relating to following four areas: prevention screening, surgery, adjuvant treatment advanced recurrent...
Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in treatment endometrial cancer.We conducted a phase 3, global, double-blind, randomized, placebo-controlled trial. Eligible patients with primary advanced stage III or IV first recurrent cancer were randomly assigned 1:1 ratio to receive either dostarlimab (500 mg) placebo, plus carboplatin (area under...
•This ESMO Clinical Practice Guideline provides key recommendations for managing endometrial cancer.•The guideline covers clinical and pathological diagnosis, staging risk assessment, treatment follow-up.•Treatment management algorithms according to groups advanced/metastatic or recurrent disease are provided.•Authorship includes a multidisciplinary group of experts from different institutions in Europe, the USA South America.•Recommendations based on available scientific data authors'...
Endometrial cancer is the most common gynecological malignancy in high-income countries. Although overall prognosis relatively good, high-grade endometrial cancers have a tendency to recur. Recurrence needs be prevented since for recurrent dismal. Treatment tailored tumor biology optimal strategy balance treatment efficacy against toxicity. Standard consists of hysterectomy and bilateral salpingo-oophorectomy. Lymphadenectomy (with ongoing studies sentinel node biopsy) enables identification...
Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived (PDGFR) -α/-β, and c-Kit. Preclinical clinical studies support VEGFR PDGFR as targets for advanced ovarian cancer treatment. This study evaluated the role pazopanib maintenance therapy in patients with whose disease did not progress during first-line chemotherapy.Nine hundred forty histologically confirmed ovary, fallopian tube, or peritoneum, International Federation...
Endometrial cancer is the most common gynecological malignancy in high- and middle-income countries. Although overall prognosis relatively good, high-grade endometrial cancers have a tendency to recur. Recurrence needs be prevented since for recurrent dismal. Treatment tailored tumor biology optimal strategy balance treatment efficacy against toxicity. Since The Cancer Genome Atlas defined four molecular subgroups of cancers, factors are increasingly used define treatment. Standard consists...
Purpose This trial evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of selinexor (KPT-330), a novel, oral small-molecule inhibitor exportin 1 (XPO1/CRM1), determined recommended phase II dose. Patients Methods In total, 189 patients with advanced solid tumors received (3 to 85 mg/m 2 ) in 21- or 28-day cycles. Pre- post-treatment levels XPO1 mRNA patient-derived leukocytes were by reverse transcriptase quantitative polymerase chain reaction, tumor biopsies examined...
<h3>Objective</h3> The aim of this study was to develop clinically relevant and evidence-based guidelines as part European Society Gynaecological Oncology's mission improve the quality care for women with gynecologic cancers across Europe. <h3>Methods</h3> Oncology Council nominated an international development group made practicing clinicians who provide patients vulvar cancer have demonstrated leadership interest in management (18 experts Europe). To ensure that statements are evidence...
This study evaluated maintenance treatment with niraparib, a potent inhibitor of poly(ADP-ribose) polymerase 1/2, in patients platinum-sensitive recurrent ovarian cancer.In this phase III, double-blind, placebo-controlled conducted at 30 centers China, adults cancer who had responded to their most recent platinum-containing chemotherapy were randomized 2 : 1 receive oral niraparib (300 mg/day) or matched placebo until disease progression unacceptable toxicity (NCT03705156). Following...
In the ENGOT-OV16/NOVA trial (ClinicalTrials.gov identifier: NCT01847274), maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, prolonged progression-free survival in patients platinum-sensitive, recurrent ovarian cancer who had response to their last platinum-based chemotherapy. The objective of study was assess clinical benefit and patient-reported outcomes partial (PR) complete (CR) therapy.A total 553 were enrolled trial. Of 203 germline BRCA mutation (gBRCAmut),...
As part of its mission to improve the quality care for women with gynecological cancers across Europe, European Society Gynaecological Oncology (ESGO) first published in 2017 evidence-based guidelines management patients vulvar cancer.To update ESGO based on new evidence addressing cancer and cover topics order provide comprehensive all relevant issues diagnosis treatment cancer.The Council nominated an international development group comprised practicing clinicians who have demonstrated...